Detalhe da pesquisa
1.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood
; 140(21): 2228-2247, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130297
2.
Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.
Pediatr Dev Pathol
; : 10935266241230600, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38468555
3.
ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
Cancer
; 129(6): 878-889, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36583229
4.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715486
5.
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Mod Pathol
; 36(6): 100166, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990279
6.
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Am J Hematol
; 98(4): 658-665, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683287
7.
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Am J Hematol
; 98(8): 1196-1203, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183966
8.
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Am J Hematol
; 98(10): 1619-1626, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37485584
9.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
10.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Lancet Oncol
; 23(3): 406-415, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074072
11.
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
Mod Pathol
; 35(9): 1212-1219, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35504958
12.
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Mod Pathol
; 35(11): 1677-1683, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690645
13.
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.
Am J Hematol
; 97(11): E408-E411, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054774
14.
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
; 97(12): 1560-1567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087091
15.
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Am J Hematol
; 97(11): 1443-1452, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054614
16.
Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
Ann Diagn Pathol
; 56: 151860, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34823075
17.
Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases.
Ann Diagn Pathol
; 59: 151951, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489185
18.
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
Cancer
; 127(17): 3113-3124, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914911
19.
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Cancer
; 127(3): 381-390, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119202
20.
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
Br J Haematol
; 192(6): 1054-1063, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33618432